Tag: Sangamo collaboration with regulatory authorities
Sangamo recently had a meeting with the FDA about their gene therapy product, ST-920, which is being developed to treat Fabry disease. The FDA has agreed that data from the Phase 1/2 STAAR study can be used for accelerated...
Breaking News
Sangamo FDA Alignment for ST-920 Accelerated Approval – TipRanks
Sangamo recently had a meeting with the FDA about their gene therapy product, ST-920, which is being developed to treat Fabry disease. The FDA...
